This study is testing a drug called AXS-14 (Esreboxetine) to see if it helps people with fibromyalgia. Researchers want to find out how long AXS-14 can help reduce symptoms before they return. You might be able to join if you are at least 18 years old, have a primary diagnosis of fibromyalgia based on specific criteria, and have not previously taken reboxetine or esreboxetine in a clinical trial. The study is currently unclear on its recruitment status and plans to enroll about 620 participants.

Study design

This is a Phase 3, randomized withdrawal study. It involves an initial open-label period where everyone receives AXS-14, followed by a double-blind period where some continue AXS-14 and others switch to a placebo.

What's involved

You would first take AXS-14 for 12 weeks. If your symptoms improve, you would then be randomly assigned to continue AXS-14 or switch to a placebo for up to another 12 weeks.

Compensation

Not stated in the trial record.

Follow-up

The study measures how long it takes for your symptoms to return, up to 12 weeks after being randomized in the second part of the study.

AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.